Regentis net loss narrows to $2.6 million in H1 FY26; operating loss widens to $2.4 million

• Regentis posted a net loss of $2.6 million, or $0.44 per share, for the six months ended June 30, 2026.
• Net loss narrowed from $3.2 million a year earlier, reflecting lower finance expenses despite higher operating spending.
• Operating loss widened to $2.4 million as R&D expenses climbed to $1.2 million; G&A expenses increased to $1.2 million.
• Cash and cash equivalents totaled $9 million at June 30, 2026; net cash used in operating activities was $2.8 million.
• GelrinC U.S. pivotal trial treated 43 of 80 patients; enrollment completion now expected around year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief on September 11, 2026, and is solely responsible for the information contained therein.